Ac-DMLD-CMK

C57BL/6 (male, 6-8 weeks old, 20-25 g, cisplatin-induced)^[1]

5 mg/kg/day

i.p.; single injection 1 hour prior to cisplatin administration

Reduced serum creatinine and blood urea nitrogen levels compared to cisplatin-only treated mice.
Alleviated renal tubular epithelial cell death.
Reduced levels of cleaved mouse Gsdme (Gsdme-N) and cleaved caspase 3, with no significant effect on full-length mouse Gsdme (Gsdme-FL).
Suppressed renal mRNA expression of Ngal, Il6,Tnfa, and Il1b; did not affect Kim1 expression.

C57BL/6 J (male, 6-8 weeks old, CLP-induced sepsis model)^[2]

5 mg/kg

i.p.; single dose (3 h before CLP surgery)

Reduced lung coefficient relative to CLP group.
Improved lung histopathology, with reduced alveolar wall thickening, congestion, bleeding, and inflammatory cell infiltration, and decreased lung injury score relative to CLP group.
Attenuated ultrastructural lung damage, including reduced type II alveolar epithelial cell edema, mitochondrial structural damage, and lamellar body vacuolization relative to CLP group.
Decreased protein expression of GSDME-N and cleaved-caspase-3 in lung tissue relative to CLP group.
Reduced mean fluorescence intensity of GSDME in lung tissue relative to CLP group.
Decreased caspase-3 activity in lung tissue relative to CLP group.
Reduced serum lactate dehydrogenase (LDH) and interleukin-6 (IL-6) levels relative to CLP group.
Decreased proportion of TUNEL-positive cells in lung tissue relative to CLP group.\nDecreased protein expression of cleaved-PARP in lung tissue relative to CLP group
nDecreased protein expression of IL-18 and IL-1β in lung tissue relative to CLP group.
Decreased lung tissue levels of pro-caspase-1, caspase-1, pro-IL-1β, and IL-1β relative to CLP group.